World Journal of Gastrointestinal Oncology最新文献

{"title":"Research and analysis of circulating tumor cell detection in the diagnosis and treatment of gastric cancer.","authors":"Han-Shu Ji","doi":"10.4251/wjgo.v17.i3.102329","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.102329","url":null,"abstract":"<p><strong>Background: </strong>Circulating tumor cells (CTCs) are crucial for improving our knowledge regarding tumor progress, prognosis, and recurrence possibility.</p><p><strong>Aim: </strong>To evaluate the role of CTCs in the early diagnosis and treatment of gastric cancer.</p><p><strong>Methods: </strong>From June 2020 to December 2021, a randomized study was conducted in our institution involving 80 patients scheduled for surgery for gastric cancer. The patients were divided into two groups: A control group that was tested for traditional serum markers and a study group that was assessed for serum CTCs.</p><p><strong>Results: </strong>In the study cohort, CTC levels did not correlate significantly with patient age, gender, or degree of tumor differentiation (<i>P</i> > 0.05). However, there was a significant correlation with the tumor-node-metastasis stage of the tumor (<i>P</i> < 0.05). In the study group, the CTC diagnostic positivity rate was 62.50% (25 out of 40 patients), while the positivity rate for conventional serum markers in the control group was 47.50% (19 out of 40 patients). The positive detection rate in the study group was significantly higher than that of the control group (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>CTCs have slight invasion and high sensitivity and specificity, presenting great value for early clinical diagnosis of recurrence and metastasis. It will improve the deceleration of disease development and increase the survival rate.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"102329"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinesin family member 14 expression and its clinical implications in colorectal cancer.","authors":"Kai Qin, Jia-Yuan Luo, Da-Tong Zeng, Wan-Ying Huang, Bin Li, Qi Li, Yan-Ting Zhan, Rong-Quan He, Wei-Jian Huang, Gang Chen, Zu-Yuan Chen, Bang-Teng Chi, Yu-Xing Tang, Rui-Xue Tang, Hui Li","doi":"10.4251/wjgo.v17.i3.102696","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.102696","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third most common cancer globally, causing over 900000 deaths annually. Risk factors include aging, diet, obesity, sedentary lifestyle, tobacco use, genetic predisposition, and inflammatory bowel disease. Despite current treatments, survival rates for advanced CRC remain low, highlighting the need for better therapeutic strategies.</p><p><strong>Aim: </strong>To evaluate both the clinical significance and the pathological implications of the Kinesin family member 14 (KIF14) expression within CRC specimens. Additionally, this study aims to investigate the interaction between nitidine chloride (NC) and KIF14, considering their potential as therapeutic targets.</p><p><strong>Methods: </strong>The expression of the KIF14 protein in CRC was analyzed using immunohistochemical staining. The integration of multicenter high-throughput data facilitated the calculation of the standardized mean difference (SMD) for <i>KIF14</i> mRNA levels. The assessment of clinical and pathological impact was enhanced by analyzing combined receiver operating characteristic curves, along with measures of sensitivity, specificity, and likelihood ratios. Additionally, clustered regularly interspaced short palindromic repeats knockout screening for cell growth and single-cell sequencing were employed to validate the significance of <i>KIF14</i> expression in CRC. Survival analysis established the prognostic value of <i>KIF14</i> in CRC. The molecular mechanism of NC against CRC was elucidated through whole-genome sequencing and enrichment analysis, and molecular docking was utilized to explore the targeting affinity between NC and KIF14.</p><p><strong>Results: </strong>KIF14 was highly expressed in 208 CRC patients. Data from 17 platforms involving 2436 CRC samples and 1320 noncancerous colorectal tissue controls indicated that <i>KIF14</i> expression was significantly higher in CRC samples, with an SMD of 1.92 (95%CI: 1.49-2.35). The area under the curve was 0.94 (95%CI: 0.92-0.96), with a sensitivity of 0.85 (95%CI: 0.78-0.90) and a specificity of 0.90 (95%CI: 0.85-0.93). The positive and negative likelihood ratios were 8.38 (95%CI: 5.39-13.02) and 0.17 (95%CI: 0.11-0.26), respectively. At the single-cell level, significant overexpression of <i>KIF14</i> was observed in CRC cells (<i>P</i> < 0.001), with 35 CRC cell lines dependent on <i>KIF14</i> for growth. The K-M plots demonstrated that <i>KIF14</i> possesses prognostic value in CRC patients within the GSE71187 and GSE103679 datasets (<i>P</i> < 0.05). Binding energy calculations indicated that KIF14 is a potential target for NC (binding energy: 10.3 kcal/mol).</p><p><strong>Conclusion: </strong><i>KIF14</i> promotes the growth of CRC cells and acts as an oncogenic factor, potentially serving as a therapeutic target for NC in the treatment of CRC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"102696"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and therapeutic strategies for familial gastrointestinal stromal tumors.","authors":"Yuan Liu, Xiao-Feng Li","doi":"10.4251/wjgo.v17.i3.100463","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.100463","url":null,"abstract":"<p><p>This editorial discusses Wang <i>et al</i>'s article on familial gastrointestinal stromal tumors (GISTs). We read with great interest this article concerning the diagnosis, treatment, and post-treatment management of patients with familial GISTs. The actual incidence of GISTs may be underestimated due to diagnostic limitations and the long-term low-risk behavior of some GISTs. The molecular landscape of GISTs is primarily driven by mutations in the <i>KIT</i> and platelet-derived growth factor receptor alpha (<i>PDGFRA</i>) genes. A subset of GISTs without these mutations known as wild-type GISTs, may harbor other rare mutations, impacting their response to targeted therapies. Clinically, patients with GISTs present with non-specific symptoms, often leading to delayed diagnosis. Genetic predispositions in familial GISTs provide insights into the genetic architecture and extragastrointestinal manifestations of GISTs. Management has evolved from surgical interventions to molecular-based therapies using tyrosine kinase inhibitors. The management of GISTs, especially in familial cases, requires a multidisciplinary approach. Cases of different gene mutations were reported in the same family, suggesting that incorporating genetic testing into routine clinical practice is crucial for the early identification of high-risk individuals and the implementation of tailored surveillance programs.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"100463"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Helicobacter pylori</i>-related serum indicators: Cutting-edge advances to enhance the efficacy of gastric cancer screening.","authors":"Hao-Tian Sun","doi":"10.4251/wjgo.v17.i3.100739","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.100739","url":null,"abstract":"<p><p><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection induces pathological changes <i>via</i> chronic inflammation and virulence factors, thereby increasing the risk of gastric cancer development. Compared with invasive examination methods, <i>H. pylori</i>-related serum indicators are cost-effective and valuable for the early detection of gastric cancer (GC); however, large-scale clinical validation and sufficient understanding of the specific molecular mechanisms involved are lacking. Therefore, a comprehensive review and analysis of recent advances in this field is necessary. In this review, we systematically analyze the relationship between <i>H. pylori</i> and GC and discuss the application of new molecular biomarkers in GC screening. We also summarize the screening potential and application of anti-<i>H. pylori</i> immunoglobulin G and virulence factor-related serum antibodies for identifying GC risk. These indicators provide early warning of infection and enhance screening accuracy. Additionally, we discuss the potential combination of multiple screening indicators for the comprehensive analysis and development of emerging testing methods to improve the accuracy and efficiency of GC screening. Although this review may lack sufficient evidence due to limitations in existing studies, including small sample sizes, regional variations, and inconsistent testing methods, it contributes to advancing personalized precision medicine in high-risk populations and developing GC screening strategies.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"100739"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine and modern technology: Network pharmacology and omics sequencing in gastric cancer.","authors":"Jessica Shapiro Gemmell, Brandon Lucke-Wold","doi":"10.4251/wjgo.v17.i3.102077","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.102077","url":null,"abstract":"<p><p>In this editorial, we comment on the article by Micucci <i>et al</i> published in the recent issue. We focus on the heterogenous nature of gastric cancer (GC) and the potential benefits of integrating traditional Chinese medicine (TCM) with the modern technology of network pharmacology (NP) and omics sequencing. GC is a heterogenous disease, as it incorporates several biochemical pathways that contribute to pathogenesis. TCM acknowledges the multifactorial, heterogenous nature of disease and utilizes an integrative approach to medicine. NP, a modern philosophy within drug development, integrates traditional knowledge of nutraceuticals and modern technologies to address the complex interactions of pathways within the body. Omics technologies, which is at the core of precision medicine, has allowed for this newfound principle of drug development. Metabolic pathways are better distinguished, leading to more targeted drug development. However, the use of omics technology needs to be employed to better characterize the subtypes of GC. This will allow TCM's use of nutraceuticals in the application of NP to better target metabolic pathways that may aid in the prevention of GC as well as enhance treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"102077"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chlorogenic acid induces hepatocellular carcinoma cell ferroptosis <i>via</i> PTGS2/AKR1C3/GPX4 axis-mediated reprogramming of arachidonic acid metabolism.","authors":"Ling Wu, Hong-Yao Chen, Jing-Ting Zhang, Ren-Yi Yang, Zhi-Bin Wang, Pei-Sen Xue, Wei Peng, Ke-Xiong Li, Wen-Hui Gao, Pu-Hua Zeng","doi":"10.4251/wjgo.v17.i3.98844","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.98844","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is an iron-dependent programmed non-apoptotic cell death characterized by the accumulation of free iron ions and lipid peroxidation. It is associated with the inactivation of glutathione peroxidase (GPX) and the accumulation of lipid peroxides within cells. Ferroptosis is closely related to the occurrence and development of hepatocellular carcinoma (HCC). Chlorogenic acid (CGA), an important bioactive component found in 61 traditional Chinese medicines such as <i>Eucommia ulmoides</i>, has been extensively studied for its effects on various malignant tumors. However, the specific role and potential mechanism of CGA in HCC remain unclear.</p><p><strong>Aim: </strong>To elucidate the anti-tumor characteristics and potential mechanisms of CGA in inducing ferroptosis in HCC cells.</p><p><strong>Methods: </strong>The effects of CGA on the proliferation, migration, and invasion of HCC cells were evaluated through <i>in vitro</i> experiments. Bioinformatics analysis combined with network pharmacology was used to study the potential targets and molecular mechanisms of CGA intervention in HCC ferroptosis. <i>In vitro</i> experiments were conducted to verify and explore the anti-HCC effects and mechanisms of CGA through the ferroptosis pathway.</p><p><strong>Results: </strong><i>In vitro</i> experiments showed that CGA dose-dependently inhibited the proliferation, invasion, and migration of HCC cells. Bioinformatics analysis combined with network pharmacology revealed that the pathway of CGA intervention in HCC cell ferroptosis was mainly enriched in the prostaglandin endoperoxide synthase 2 (PTGS2)/aldo-keto reductase family 1 member C3 (AKR1C3)/GPX4 signaling pathway, which was associated with arachidonic acid. <i>In vitro</i> experiments further confirmed that CGA-induced ferroptosis in HCC cells was related to mitochondrial damage through the reprogramming of arachidonic acid metabolism by regulating the PTGS2/AKR1C3/GPX4 signaling pathway.</p><p><strong>Conclusion: </strong>This study demonstrates that CGA inhibits HCC cell proliferation, migration, and invasion by inducing ferroptosis through the PTGS2/AKR1C3/GPX4 axis, suggesting its potential as a novel ferroptosis inducer or anti-HCC drug.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"98844"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and global trends of precancerous lesions of gastric cancer: A bibliometric analysis.","authors":"Yuan-Ping Jia, Dian-Chun Liu, Ting-Lan Cao, Hui-Zhong Jiang, Tao Li, Yuan Li, Xia Ding","doi":"10.4251/wjgo.v17.i3.102111","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.102111","url":null,"abstract":"<p><strong>Background: </strong>Precancerous lesions of gastric cancer (PLGC) represent a critical pathological stage in the development of intestinal gastric cancer. Early detection and diagnosis are key to reducing the incidence of gastric cancer. Substantial advancements have been made in PLGC research in recent years, making it necessary to provide updated reviews using bibliometric methods. We hypothesize that this review will identify emerging trends, key research areas, and gaps in PLGC research, providing insights that could guide future studies and enhance prevention strategies.</p><p><strong>Aim: </strong>To comprehensively review the current state of research on PLGC, examining development trends and research hotspots.</p><p><strong>Methods: </strong>We conducted a bibliometric analysis of PLGC-related studies published between 2004 and 2023 using the Web of Science Core Collection database. We employed Software, including VOSviewer, CiteSpace, R software, and SCImago Graphica, to map scientific networks and visualize knowledge trends in terms of publication volume, countries/regions, institutions, journals, authors, and keywords.</p><p><strong>Results: </strong>A total of 4097 articles were included, and overall publication volume showed an increasing trend. Over the past two decades, China published the most articles, followed by the United States, Japan, South Korea, and Italy. Among the top 10 contributors, the United States ranked highest in institutions, authors, and citations and demonstrated the strongest international collaboration. Research keywords in this field were clustered into three main categories: Risk factors, pathogenesis, and diagnosis and treatment. Pathogenesis and molecular biomarkers remain key areas of focus. Future research should explore the mechanisms of gut microbiota, immune microenvironment, metabolic reprogramming, and epigenetics. Advanced technologies, including single-cell sequencing, spatially resolved analysis, multi-omics approaches, artificial intelligence, and machine learning, will likely accelerate in-depth investigations of PLGC.</p><p><strong>Conclusion: </strong>PLGC research has rapidly developed in recent years, gaining considerable attention. This bibliometric analysis reveals research state and emerging trends over the past 20 years, providing insights for future studies.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"102111"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of progression to high-grade intraepithelial neoplasia and gastric cancer: A multi-center prospective study in Anhui Province, China.","authors":"Ying-Ling Liu, Jie Liu, Ye-Tao Wang","doi":"10.4251/wjgo.v17.i3.103296","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.103296","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is one of the most common cancers worldwide, especially in East Asia.</p><p><strong>Aim: </strong>To explore the clinical outcomes and progression-related factors of low-grade intraepithelial neoplasia (LGIN) in the gastric mucosa and provide valuable guidance for improving treatment efficacy.</p><p><strong>Methods: </strong>A total of 357 patients diagnosed with LGIN based on initial pathological examination in Anhui Provincial Hospital or three other medical consortium units between January 2022 and June 2024 were included. Among them, 296 patients were followed up with endoscopic and biopsy pathology. Logistic regression was utilized to analyze the relevant risk factors for LGIN progression in the gastric mucosa.</p><p><strong>Results: </strong>The distribution sites of LGIN among the 357 patients were as follows: Gastric antrum (54.6%), gastric cardia (24.1%), gastric angulus (8.7%), gastric body (4.8%), gastric fundus (4.8%), and multiple sites (3.1%). Additionally, of the 357 patients with LGIN, 112 (31.4%) developed ulceration and 59 (16.5%) experienced gastric polyps. Furthermore, 231 of the 357 (64.71%) patients with LGIN tested positive for <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection. The <i>H. pylori</i> infection rates of the patients with LGIN with accompanying atrophy, intestinal metaplasia, and gastric ulcer were 51.95%, 59.31%, and 28.57%, respectively. Multivariate logistic regression analysis showed that age ≥ 60 years [odds ratio (OR) = 3.063, 95% confidence interval (CI): 1.351-6.945, <i>P</i> = 0.007], <i>H. pylori</i> infection (OR = 3.560, 95%CI: 1.158-10.949, <i>P</i> = 0.027), multiple locations (OR = 10.136, 95%CI: 2.045-50.237, <i>P</i> = 0.005), lesion size ≥ 2 cm (OR = 3.921, 95%CI: 1.664-9.237, <i>P</i> = 0.002), and gastric ulcer (OR = 2.730, 95%CI: 1.197-6.223, <i>P</i> = 0.017) were predictive factors for LGIN progression.</p><p><strong>Conclusion: </strong>LGIN progression is closely related to age, <i>H. pylori</i> positivity, multiple locations, lesion size ≥ 2 cm, and gastric ulcer. Thus, actively identifying these risk factors in patients with LGIN may have certain clinical significance in preventing further tumor progression.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"103296"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: The role of technological advances in shaping gastrointestinal oncological outcomes.","authors":"Nuno J G Rama, Inês Sousa","doi":"10.4251/wjgo.v17.i3.101752","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.101752","url":null,"abstract":"<p><p>Gastrointestinal (GI) cancers are highly prevalent and considered a major global health challenge. Their approach has undergone a remarkable transformation over the past years due to the development of new technologies that enabled better outcomes regarding their diagnosis and management. These include artificial intelligence, robotics, next-generation sequencing and personalized medicine. Nonetheless, the integration of these advances into everyday clinical practice remains complex and challenging as we are still trying to figure out if these innovations tangibly improve oncological outcomes or if the current state of art should remain as the gold standard for the treatment of these patients. Additionally, there are also some issues regarding ethical subjects, data privacy, finances and governance. Precision surgery concept has evolved considerably over the past decades, especially for oncological patients. It aims to customize medical treatments and to operate on those patients who most likely will benefit from a specific surgical procedure. In the future, to improve GI oncological outcomes, a delicate balance between technological advances adoption and evidence-based care should be chased. As we move forward, the question will be to harness the power of innovation while keeping up the highest standards of patient care.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"101752"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma: A case report.","authors":"Ming-Zhi Hao, Hai-Lan Lin, Yu-Bin Hu, Qi-Zhong Chen, Zhang-Xian Chen, Lin-Bin Qiu, Duan-Yu Lin, Hui Zhang, De-Chun Zheng, Zhu-Ting Fang, Jing-Feng Liu","doi":"10.4251/wjgo.v17.i3.100861","DOIUrl":"https://doi.org/10.4251/wjgo.v17.i3.100861","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) has become a growing health concern globally. Microvascular invasion and high tumor burden are key factors limiting the curative effect of selective internal radiation therapy (SIRT).</p><p><strong>Case summary: </strong>This case study reports a 49-year-old woman who was diagnosed with China Liver Cancer Staging (CNLC) IIIa HCC and > 15 cm tumor diameter. Initially, due to insufficient future liver remnant and vascular invasion, the tumor was unresectable; however, radical hepatectomy was performed after successful conversion therapy with SIRT using yttrium-90 (⁹⁰Y) resin microspheres followed by hepatic arterial infusion chemotherapy (HAIC) with tyrosine kinase inhibitor (TKI) and anti-programmed death-1 (PD-1) antibody. SIRT using ⁹⁰Y resin microspheres was given by the right hepatic artery and chemoembolization was simultaneously performed in the tumor's feeding vessels from the right diaphragmatic artery. HAIC was followed every three weeks with lenvatinib and tislelizumab. At 4 months post-SIRT, the tumor was downstaged to CNLC Ib and the patient successfully underwent hepatectomy. The histopathological examination of the resected specimen showed extensive necrosis.</p><p><strong>Conclusion: </strong>This case study provides evidence for an integrated treatment strategy combining SIRT and HAIC with TKI and anti-PD-1 antibodies for patients with large HCC and microvascular invasion. Further confirmatory trials are required in the future.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 3","pages":"100861"},"PeriodicalIF":2.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}